Theralase Quarterly Newsletter Dec 2011


Published on

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Theralase Quarterly Newsletter Dec 2011

  1. 1. Theralase Quarterly Newsletter - December 2011An update for clients, investors and employees Theralase’s Patented Photo Dynamic Compound (PDC) Effective in Destruction of Cancerous Tumours in Live AnimalsTheralase announced on December 1st that its patented light activated PDC technology was successful indestroying cancerous tumours located under the skin of a live animal. We are excited that our PDCtechnology has achieved this critical milestone because we have now validated our technology in thedestruction of cancerous tumours in live animals. The Theralase PDC treatment was successful and welltolerated by the animals and as a result, this preclinical success will help the Company to identify theleading PDC to take forward for additional animal and human cancer destruction applications. Now thatour PDC technology has been proven successful in the destruction of cancerous tumours in animals, thismay lead to a new significant revenue stream for the Company in the destruction of cancerous tumoursin companion animals and humans in the not too distant future. Theralase Light Activated Photo Dynamic Compounds Successfully Destroy E. coli BacteriaTheralase has developed a new application for its patented Photo Dynamic Compounds (PDCs);specifically, the destruction of Escherichia coli, commonly known as E. coli, a widely prevalent diseasecausing bacteria. Theralase announced on September 14th, that our research demonstrated that ourPhoto Dynamic Therapy (PDT) destruction of E. coli bacteria is effective and represents a significantopportunity in the area of disinfection and sterilization of bacterial pathogens that may cause seriousand potentially life-threatening illness. Commercialization of these technologies becomes more andmore apparent, as our research and development progresses, allowing us the opportunity to introducethese technologies to the world in a variety of diverse applications. The next steps for Theralase will be 1
  2. 2. to prove out the technology further in a lab setting and then develop a pilot project with a major foodmanufacturer. Theralase and George Brown College Join in Government-Funded Research to Combat Food ContaminationIn the wake of many outbreaks of consumer food contaminations associated with microbial pathogenssuch as Listeria monocytogenes (Listeria) and Escherichia coli (E. coli) and their various strains, Theralasecompleted a the study with George Brown College to determine the feasibility of using our patentedPDCs for sanitation in the food service, food manufacturing and medical industries. Given their historyand pedigree in culinary arts and additional focus on food applied research, the George Brown CollegeCentre for Hospitality and Culinary Arts was a perfect partner for applied research in new and innovativesanitation protocols and techniques using the company’s patented lasers and photo dynamiccompounds. The results proved that the Theralase PDC technology is highly effective in the destructionof food related pathogens. Theralase Introduces Low Priced Laser Series - New TLC-900 Laser Series Offers Theralase’s Renowned Clinical Performance at Lower PricesOn November 17th Theralase launched a new version of the high performance Theralase TLC-1000therapeutic medical laser series, known as the Theralase TLC-900 series, which effectively eliminates thecontroller and allows the practitioner to operate the laser probes independently. This TLC-900 systemallows the practitioner the ability to benefit from the high performance Theralase laser systemtechnology, albeit with less features and versatility than the TLC-1000 series, but at an overall costsavings. We believe that this will open up the therapeutic laser market and give practitioners the abilityto choose a high performing product, such as the Theralase, at the same price points as lower end, non-effective, competitive technology. Theralase Closes Equity FinancingOn October 25th Theralase Technologies Inc. announced that it closed a non-brokered private placementof 1,050,000 units at a price of Cdn $0.40 per Unit for gross proceeds of Cdn $420,000.00. Each Unitconsists of one common share in the capital of the Company and one-half of one non-transferablecommon share purchase warrant. Each whole Warrant entitles the purchaser to purchase one additionalcommon share in the capital of the Company until October 25, 2013 at a price of Cdn $0.60 per WarrantShare. The securities issued under the Private Placement including any shares issued upon exercise ofthe Warrants are subject to a four month hold period, expiring February 25, 2012.The company intends to utilize the proceeds of the offering to provide additional working capital tofurther develop the Companys prospects in a number of areas; specifically:• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital,University Health Network. 2
  3. 3. • Research and development of Photo Dynamic Compounds used in conjunction with the patentedTheralase laser technology in the destruction of bacteria in the area of food safety.• TLC-1000 and TLC-900 series therapeutic medical laser marketing and sales expansion into the US.• TLC-2000 therapeutic medical biofeedback laser commercialization. Theralase Publishes White Paper On October 27th Theralase released a pivotal White Paper written by Chief Scientific Officer, Arkady Mandel, MD, Ph.D., D.Sc. entitled “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)”Low Level Laser Therapy (LLLT) is a rapidly growing modality used in the rehabilitation and physicaltherapy markets. A number of safe and beneficial therapeutic effects of LLLT have been reported innumerous clinical conditions; however, despite many reports of positive findings from experimentsconducted in-vitro, in-vivo animal models and in randomized controlled clinical trials worldwide, the useof this scientifically proven, clinically effective, non-invasive and anti-inflammatory human modality hasyet to find mainstream adoption by medical doctors.The aim of the White Paper is to:1) introduce the unfamiliar reader, with some medical background, to the contemporary concept of LLLTand its pathophysiological significance,2) review the role of the mitochondrial pathway in the mechanisms of LLLT,3) provide necessary practical guidance based on scientific and clinical experience,4) assist manufacturers in their research and development,5) help health care practitioners choose and use an adequate light therapy device,6) outline the prospects of LLLT as an avenue to treat chronic inflammation and pain and to aid in aneffective clinical practice.The White Paper may be accessed from will continue to focus on increasing product sales of the TLC-1000 laser technology and thenewly released TLC-900 controllerless laser series in the Canadian, US and international markets in 2012,supported by new independent scientific research confirming the effectiveness of Theralase’sproprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedbacktechnology for launch in the third quarter of 2012, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.The groundwork has been laid for significant growth. Our proven patented technology has no equal andour ability to dramatically scale sales and marketing geographically as well as demographically will allowTheralase a significant first mover market advantage. Theralase is currently debt free as it utilizes itsprofits from the sale of its TLC-1000 Therapeutic Medical Laser platform to pay for its future growth inthe form of the launch of the TLC-900 series, the launch of the TLC-2000 Biofeedback Therapeutic Laser 3
  4. 4. Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer DestructionTechnology.For more information please contact:Roger Dumoulin-WhitePresident & CEO,416-447-8455 ext. 225rwhite@theralase.comGreg BewshDirector of Investor Relations,416-447-8455 ext. 4